"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle â€“ every drug that FDA approves â€“ carries some risk. One of the first lines of defense against "...
Infasurf Side Effects Center
Infasurf (calfactant) is used to treat or prevent respiratory distress syndrome (RDS) in a premature baby whose lungs have not fully developed. It is a lung surface acting agent, or "surfactant." It helps the lungs function normally. Infasurf causes few side effects. There is a possibility the baby will have breathing difficulties during treatment, and these problems may require further treatment.
Each dose of Infasurf is 3 mL/kg body weight at birth. Infasurf has been administered every 12 hours for a total of up to 3 doses. Drug interactions between Infasurf and other medications are not expected to occur. Your baby's caregivers will manage and monitor all medications given to your baby during treatment in the NICU. Because this drug is intended for premature babies, it is unlikely to be used by pregnant or breastfeeding women.
Our Infasurf (calfactant) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Infasurf in Detail - Patient Information: Side Effects
Calfactant causes few side effects. There is a possibility that the baby will have breathing difficulties during the calfactant treatment, and these problems may require further treatment by health care professionals. Your baby will remain under constant supervision during treatment with calfactant.
Read the entire detailed patient monograph for Infasurf (Calfactant) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Infasurf FDA Prescribing Information: Side Effects
The most common adverse reactions associated with Infasurf (calfactant) dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death.
The incidence of common complications of prematurity and RDS in the four controlled Infasurf (calfactant) trials are presented in Table 3. Prophylaxis and treatment study results for each surfactant are combined.
Table 3 - Common Complications of Prematurity and RDS in
|Patent ductus arteriosus||47||48||45||48|
|Severe intracranial hemorrhage a||12||10||9||7|
|IVH and PVLb||7||3||5||5|
|Pulmonary air leaks||12||22||15||15|
|Pulmonary interstitial emphysema||7||17||10||10|
|a Grade III and IV by the method of Papile.
b Patients with both intraventricular hemorrhage and periventricular leukomalacia.
Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled in 5 centers that participated in the Infasurf (calfactant) vs. Exosurf Neonatal® controlled trials demonstrated significant developmental delays in equal percentages of Infasurf (calfactant) and Exosurf Neonatal® patients.
Read the entire FDA prescribing information for Infasurf (Calfactant) »
Additional Infasurf Information
Report Problems to the Food and Drug Administration
Find out what women really need.